ANIK Anika Therapeutics, Inc.

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.

BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Recent price strength puts OptimumBank, EuroDry, Enova International, Anika Therapeutics and GEO in focus as August stocks with momentum.

Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.

Revenue hit $32.6 million with record commercial channel sales and expanded margins.

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

The latest analyst update on Anika Therapeutics centers on a higher price target, with modeled fair value moving from US$16 to US$21 per share. Research commentary describes this shift as a reflection of greater confidence in the company’s ability to sustain profitability, supported by the recent Q2 beat, stronger margins, and raised guidance. As you read on, you will see how this evolving narrative is taking shape and what to watch to stay in step with it. Stay updated as the Fair Value for...

Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.

Anika Therapeutics Inc (ANIK) reports robust growth in commercial and international channels, while navigating pricing pressures and regulatory uncertainties.

Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call

Anika Therapeutics (NASDAQ:ANIK) reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability. Total revenue rose 16% year over year to $32.6 million